Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DSM Biologics, a business unit of DSM Pharmaceutical Products, and Crucell, a biopharmaceutical company, have signed a commercial licensing agreement with Gedeon Richter, a developer and marketer of pharmaceutical products, allowing Gedeon Richter to develop and produce certain biopharmaceuticals on the PER.C6 platform. Other terms of the agreement were not disclosed.
Subscribe to our email newsletter
Crucell’s PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies.
DSM’s XD technology has been developed as a proprietary system to drive yield improvements in mammalian systems. ‘XD’ stands for extreme density, as the process is able to push the cell density within the bioreactor to maximum productivity.